Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2020 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Appointment of Robert K. Ho as Chief Financial Officer

SEATTLE, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
February 24, 2020 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference

SEATTLE, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
February 06, 2020 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks Idea Forum | Oncology Day

SEATTLE, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
December 20, 2019 16:01 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEATTLE, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
December 17, 2019 22:26 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
December 17, 2019 16:38 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
December 05, 2019 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Scientific Advisory Board

SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
November 26, 2019 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

SEATTLE, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
November 13, 2019 09:15 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Corporate Update and Third Quarter 2019 Financial Results

SEATTLE, Wash., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
September 19, 2019 08:00 ET | Source: Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics Announces Additions to Management Team

Leslie Aberman, Vice President, Legal Affairs and Intellectual PropertySamantha Willing, Vice President, People SEATTLE, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc....

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right